Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources

BACKGROUND: Biologics directed against the T-helper (Th)-17 pathway have been approved for several inflammatory diseases. Interleukin (IL)-17 is involved in anti-Candida host defense, and clinical trials suggested increased candidiasis incidence during IL-17 inhibitor therapy. We describe the worldw...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidson, Linda, van den Reek, Juul M.P.A., Bruno, Mariolina, van Hunsel, Florence, Herings, Ron M.C., Matzaraki, Vasiliki, Boahen, Collins K., Kumar, Vinod, Groenewoud, Hans M.M., van de Veerdonk, Frank L., Netea, Mihai G., de Jong, Elke M.G.J., Kullberg, Bart Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671639/
https://www.ncbi.nlm.nih.gov/pubmed/34950923
http://dx.doi.org/10.1016/j.lanepe.2021.100266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671639/
https://www.ncbi.nlm.nih.gov/pubmed/34950923
http://dx.doi.org/10.1016/j.lanepe.2021.100266

Ejemplares similares